Investing.com
Earnings call: Bluebird bio reports Q1 2024 results, anticipates growth By Investing.com
Bluebird bio Inc. (BLUE) has announced its first-quarter 2024 financial results, highlighting the first commercial cell collection for LYFGENIA, its gene therapy for sickle cell disease. With ...
4 hours ago